MA32961B1 - Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique - Google Patents

Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique

Info

Publication number
MA32961B1
MA32961B1 MA34008A MA34008A MA32961B1 MA 32961 B1 MA32961 B1 MA 32961B1 MA 34008 A MA34008 A MA 34008A MA 34008 A MA34008 A MA 34008A MA 32961 B1 MA32961 B1 MA 32961B1
Authority
MA
Morocco
Prior art keywords
hemifumarate
ethyl
benzyloxyimino
azetidin
salmon
Prior art date
Application number
MA34008A
Other languages
Arabic (ar)
English (en)
Inventor
Lech Ciszewski
La Cruz Marilyn De
Piotr H Karpinski
Michael Mutz
Christian Riegert
Caspar Vogel
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32961(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32961B1 publication Critical patent/MA32961B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte sur un sel hémifumarate d'acide 1-(4-{1-[(E)-4-cyclohexyl-3-trifluorométhyl-benzyloxyimino]-éthyl}-2-éthyl-benzyl)-azétidine-3-carboxylique (Composé I), sur des compositions pharmaceutiques comprenant ce sel, sur des procédés de formation de ce sel et sur son utilisation dans un traitement médical. De plus, la présente invention porte également sur de nouvelles formes polymorphes de la forme sel hémifumarate du Composé I, ainsi que sur des compositions pharmaceutiques comprenant ces formes polymorphes, sur des procédés permettant de les obtenir et sur leur utilisation dans un traitement médical.
MA34008A 2008-12-18 2009-12-16 Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique MA32961B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18
PCT/US2009/068143 WO2010080409A1 (fr) 2008-12-18 2009-12-16 Sel hémifumarate d'acide 1-[4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino]-éthyl]-2-éthyl-benzyl]-azétidine-3-carboxylique

Publications (1)

Publication Number Publication Date
MA32961B1 true MA32961B1 (fr) 2012-01-02

Family

ID=42236293

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34008A MA32961B1 (fr) 2008-12-18 2009-12-16 Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique

Country Status (35)

Country Link
US (7) US20120115840A1 (fr)
EP (2) EP2379497B1 (fr)
JP (1) JP5627597B2 (fr)
KR (5) KR20160064245A (fr)
CN (2) CN102256943A (fr)
AR (3) AR074694A1 (fr)
AU (1) AU2009335924B2 (fr)
BR (1) BRPI0923176B8 (fr)
CA (2) CA2951479A1 (fr)
CL (1) CL2011001490A1 (fr)
CO (1) CO6390104A2 (fr)
CY (2) CY1114662T1 (fr)
DK (2) DK2379497T3 (fr)
EC (1) ECSP11011210A (fr)
ES (2) ES2631203T3 (fr)
HR (2) HRP20131106T1 (fr)
HU (1) HUE034819T2 (fr)
IL (3) IL253845B (fr)
JO (1) JO2894B1 (fr)
LT (1) LT2676953T (fr)
MA (1) MA32961B1 (fr)
MX (1) MX2011006609A (fr)
MY (1) MY152669A (fr)
NZ (1) NZ593061A (fr)
PE (2) PE20120336A1 (fr)
PL (2) PL2379497T3 (fr)
PT (2) PT2676953T (fr)
RS (2) RS56110B1 (fr)
RU (1) RU2518114C3 (fr)
SG (1) SG171785A1 (fr)
SI (2) SI2379497T1 (fr)
TW (2) TWI591055B (fr)
UY (1) UY32330A (fr)
WO (1) WO2010080409A1 (fr)
ZA (1) ZA201103709B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501442B1 (en) * 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
EP3129006B1 (fr) 2014-04-10 2021-01-27 Novartis AG Formulation d'immunosuppresseur
EP4074312B1 (fr) * 2014-04-10 2026-02-25 Novartis AG Régime posologique à libération immédiate de siponimod pour le traitement de maladies auto-immunes
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (fr) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Modulateurs azétidine du récepteur de la sphingosine 1-phosphate
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11390583B2 (en) 2017-09-27 2022-07-19 Dr. Reddy's Laboratories Limited Process for preparation of Siponimod, its salts and solid state forms thereof
AU2018341136A1 (en) * 2017-09-27 2020-03-12 Novartis Ag Parenteral formulation comprising siponimod
RU2020114751A (ru) * 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
EP3687530A1 (fr) * 2017-09-29 2020-08-05 Novartis AG Schéma posologique de siponimod
WO2019144094A1 (fr) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Acide fumarique siponimod cristallin et polymorphes de celui-ci
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
KR20200072795A (ko) 2018-12-13 2020-06-23 고려대학교 산학협력단 옥시이미노메틸벤젠 유도체를 유효성분으로 포함하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (fr) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Formes solides cristallines de siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
US12304905B2 (en) 2019-03-28 2025-05-20 1ST Biotherapeutics, Inc. Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof
EP3972954A1 (fr) 2019-05-21 2022-03-30 Synthon B.V. Sel d'acide maléique et d'acide fumarique siponimod
WO2021084068A1 (fr) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
EP4139282A2 (fr) * 2020-05-29 2023-03-01 Cipla Limited Procédés de préparation de modulateurs du récepteur de la sphingosine 1-phosphate et leurs formes solides
AU2021346866B2 (en) * 2020-09-25 2024-05-30 Synthon B.V. Siponimod salts and cocrystals
CN116456977A (zh) * 2020-09-25 2023-07-18 斯索恩有限公司 西尼莫德盐和共晶
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (fr) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 Formes cristallines de sel hémifumarate d'un composé d'acide carboxylique et procédé de préparation associé
EP4313941A1 (fr) 2021-03-26 2024-02-07 OLON S.p.A. Nouveau composé cristallin d'hémifumarate de siponimod
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
ES2073868T3 (es) * 1991-06-04 1995-08-16 Fujisawa Pharmaceutical Co Una composicion profilactica/terapeutica para la pleuroneumonia del cerdo.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0666868B2 (fr) 1992-10-28 2006-06-14 Genentech, Inc. Usage d'anticorps anti-VEGF pour le traitement du cancer
AU682515B2 (en) * 1993-06-08 1997-10-09 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DK0916651T3 (da) * 1996-04-04 2003-12-01 Sankyo Co Phenylalkylcarboxylsyrederivater
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (fr) 1996-09-13 1998-03-19 Sugen, Inc. Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
WO2000009495A1 (fr) 1998-08-11 2000-02-24 Novartis Ag Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
CA2433181C (fr) * 2000-12-29 2005-11-22 Pfizer Limited Fumarate d'amlodipine
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (fr) 2003-06-13 2004-12-23 Stephen Dichiera Support de lit reglable et lit
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
CA2589265A1 (fr) * 2004-11-29 2006-06-01 Novartis Ag Posologie d'un agoniste du recepteur s1p
US20080279932A1 (en) * 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20081157A1 (es) * 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno

Also Published As

Publication number Publication date
US20120115840A1 (en) 2012-05-10
CA2951479A1 (fr) 2010-07-15
AR074694A1 (es) 2011-02-02
ECSP11011210A (es) 2011-08-31
EP2676953A1 (fr) 2013-12-25
BRPI0923176B1 (pt) 2020-12-01
IL253845B (en) 2022-08-01
CY1114662T1 (el) 2016-10-05
SI2379497T1 (sl) 2013-12-31
IL213071A0 (en) 2011-07-31
US20230357142A9 (en) 2023-11-09
DK2379497T3 (da) 2013-11-25
WO2010080409A1 (fr) 2010-07-15
EP2676953B1 (fr) 2017-03-22
BRPI0923176A2 (pt) 2016-02-16
UY32330A (es) 2010-07-30
JP5627597B2 (ja) 2014-11-19
CO6390104A2 (es) 2012-02-29
BRPI0923176A8 (pt) 2017-09-12
TWI591055B (zh) 2017-07-11
MX2011006609A (es) 2011-06-30
RS56110B1 (sr) 2017-10-31
HRP20131106T1 (hr) 2013-12-20
US20240239743A1 (en) 2024-07-18
US20140005162A1 (en) 2014-01-02
RS53041B (sr) 2014-04-30
CL2011001490A1 (es) 2012-01-13
RU2011129222A (ru) 2013-01-27
CN104803902A (zh) 2015-07-29
TW201509909A (zh) 2015-03-16
CN102256943A (zh) 2011-11-23
KR20180006492A (ko) 2018-01-17
EP2379497A1 (fr) 2011-10-26
HRP20170916T1 (hr) 2017-09-22
AU2009335924B2 (en) 2012-11-08
KR20170062554A (ko) 2017-06-07
US20180118678A1 (en) 2018-05-03
SG171785A1 (en) 2011-07-28
AR112227A2 (es) 2019-10-02
CA2747437A1 (fr) 2010-07-15
ES2631203T3 (es) 2017-08-29
RU2518114C3 (ru) 2021-11-24
PT2379497E (pt) 2013-11-29
IL253845A0 (en) 2017-09-28
MY152669A (en) 2014-10-31
CA2747437C (fr) 2018-08-21
HUE034819T2 (en) 2018-02-28
JO2894B1 (en) 2015-09-15
AR121635A2 (es) 2022-06-22
KR20160064245A (ko) 2016-06-07
ES2436197T3 (es) 2013-12-27
US20220402870A1 (en) 2022-12-22
KR101885052B1 (ko) 2018-08-02
PE20120336A1 (es) 2012-04-30
LT2676953T (lt) 2017-06-26
SI2676953T1 (sl) 2017-07-31
US20150175536A1 (en) 2015-06-25
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
PE20142374A1 (es) 2015-01-30
US20210323915A1 (en) 2021-10-21
TW201035048A (en) 2010-10-01
AU2009335924A1 (en) 2011-06-30
KR20110096584A (ko) 2011-08-30
CY1119037T1 (el) 2018-01-10
HK1159631A1 (en) 2012-08-03
EP2379497B1 (fr) 2013-08-21
ZA201103709B (en) 2012-01-25
KR20160129915A (ko) 2016-11-09
JP2012512881A (ja) 2012-06-07
IL294514A (en) 2022-09-01
PT2676953T (pt) 2017-06-29
DK2676953T3 (en) 2017-07-03
NZ593061A (en) 2013-08-30
BRPI0923176B8 (pt) 2021-05-25
PL2379497T3 (pl) 2014-01-31
RU2518114C2 (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
MA32961B1 (fr) Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique
BRPI0922457A2 (pt) forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
EP2235857A4 (fr) Signalisation de la présence de trames d'extension
EP2580165A4 (fr) Retrait de composés physiologiquement actifs d'eaux usées
EP2250276A4 (fr) Organismes de conception pour production de butanol photobiologique à partir de dioxyde de carbone et d eau
EP2097111A4 (fr) Hétérodimères d'acide glutamique
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
EA201170922A1 (ru) Производные сульфонамида
DE602007008851D1 (de) Ektionsmittel
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
EP2094118A4 (fr) Composition amelioree d'acide peracetique
EP2545713A4 (fr) Détermination d'un mode de prédiction intra d'une unité de codage d'image et d'une unité de décodage d'image
EP2345258A4 (fr) Élimination des scintillements des trames i pour un codage vidéo multithread parallèle au gop
EP2017263A4 (fr) Derive acide carboxylique inferieur d'heteroarylamide
SI1771441T1 (sl) Novi amidi karboksilnih kislin kot inhibitorji faktorja XA
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
EP2491924A4 (fr) Diclofénac sodique à base de pâte contenant de l'eau
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы